Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
Healthy Volunteers
ID04227678

Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

Led by Université de Sherbrooke · Updated on 2026-02-10

16

Participants Needed

1

Research Sites

12 weeks

Total Duration

On this page

Sponsors

U

Université de Sherbrooke

Lead Sponsor

I

Institut de Recherches Cliniques de Montreal

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research focuses on people with Lipoprotein Lipase Deficiency (LPLD), a condition where the enzyme lipoprotein lipase is lacking, causing very high levels of triglycerides in the blood. These patients often experience symptoms like abdominal pain and dizziness after meals and risk recurrent pancreatitis. The study aims to understand how LPLD affects the way dietary fatty acids are stored and used by organs, especially the heart, and how new treatments might influence this process. Participants will undergo three visits including a screening and two metabolic studies spaced 7 to 14 days apart. Each metabolic study lasts 9 hours and involves eating a low-fat liquid meal while researchers use PET scans and stable isotopic tracers to track fatty acid metabolism. The studies compare conditions with and without an intravenous heparin injection given before the meal. The groups include healthy controls and LPLD patients, each tested with and without heparin. During the study, participants will have detailed evaluations including heart function scans, blood tests, and metabolic assessments at specific intervals. Researchers will measure how dietary fatty acids are distributed to organs, used by the heart, and metabolized overall. The study also monitors insulin sensitivity, glucose turnover, and other metabolic markers over months. This comprehensive monitoring helps understand the disease impact and treatment effects over time.

CONDITIONS

Brief Title

Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

Who Can Participate

Age: 18Years - 75Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • Lipoprotein Lipase Deficiency (LPLD) subjects with a history of fasting triglycerides over 5 mmol/l and confirmed homozygote or compound heterozygote LPL-gene mutation
  • Healthy control subjects with fasting glucose below 5.6 mmol/l, 2-hour post 75g OGTT glucose below 7.8 mmol/l, HbA1c below 5.8%, and fasting triglycerides below 1.5 mmol/l
  • Willing and able to follow the study protocol
  • Signed informed consent indicating understanding of the study purpose
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Known cardiovascular disease as shown by medical history, physical exam, or abnormal ECG
  • Treatment with fibrates, thiazolidinediones, beta-blockers, or other drugs affecting lipid or carbohydrate metabolism (except statins, metformin, and some antihypertensives that can be paused)
  • Use of antihypertensive medication (only for LPLD individuals)
  • Liver or kidney disease or uncontrolled thyroid disorder
  • Previous diagnosis of heparin-induced thrombocytopenia
  • Use of oral anticoagulants or platelet aggregation inhibitors
  • History of major bleeding event
  • Smoking more than 1 cigarette per day or drinking more than 2 alcoholic beverages daily
  • Female participants who are pregnant, breastfeeding, planning pregnancy, or pre-menopausal with a positive pregnancy test at enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Postprandial Metabolic Studies

Duration - 2 to 4 weeks with 7 to 14 days between study visits

Participants undergo two metabolic study visits in random order, including ingestion of a low fat liquid meal with and without intravenous heparin. Each study lasts 9 hours involving metabolic measurements using PET and stable isotopic tracer methods.

2 visits (each lasting approximately 9 hours)

Trial Site Locations

Total: 1 location

1

Centre de recherche du CHUS

Sherbrooke, Quebec, Canada, J1H 5N4

Actively Recruiting

Loading map...

Research Team

F

Frédérique Frisch

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

4

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here